Key clinical point: Psoriatic arthritis (PsA) was not associated with a significant increase in risk for all-cause mortality in the more recent era between 2003 and 2018. Moreover, the major causes of death in PsA were not different than those commonly reported in the general population.

Major finding: The number of deaths was similar in PsA and control groups (8.9% and 7.9%, respectively), and the association between PsA and a higher risk for all-cause mortality was not significant (hazard ratio, 1.02; 95% confidence interval, 0.90-1.15). In the general population, malignancy (26.0%) and ischemic heart disease (15.8%) were the leading causes of death in patients with PsA.

Study details: Findings are from an analysis of a cohort of 5,275 adults newly diagnosed with PsA between 2003 and 2018, matched with 21,011 control participants and followed for 7.2±4.4 years.

Disclosures: The study did not report any source of funding. No conflict of interests was reported.

Source: Haddad A et al. J Rheumatol. 2021 Jul 15. doi: 10.3899/jrheum.210159. 

Key clinical point: Psoriatic arthritis (PsA) was not associated with a significant increase in risk for all-cause mortality in the more recent era between 2003 and 2018. Moreover, the major causes of death in PsA were not different than those commonly reported in the general population.

Major finding: The number of deaths was similar in PsA and control groups (8.9% and 7.9%, respectively), and the association between PsA and a higher risk for all-cause mortality was not significant (hazard ratio, 1.02; 95% confidence interval, 0.90-1.15). In the general population, malignancy (26.0%) and ischemic heart disease (15.8%) were the leading causes of death in patients with PsA.

Study details: Findings are from an analysis of a cohort of 5,275 adults newly diagnosed with PsA between 2003 and 2018, matched with 21,011 control participants and followed for 7.2±4.4 years.

Disclosures: The study did not report any source of funding. No conflict of interests was reported.

Source: Haddad A et al. J Rheumatol. 2021 Jul 15. doi: 10.3899/jrheum.210159. 

Key clinical point: Psoriatic arthritis (PsA) was not associated with a significant increase in risk for all-cause mortality in the more recent era between 2003 and 2018. Moreover, the major causes of death in PsA were not different than those commonly reported in the general population.

Major finding: The number of deaths was similar in PsA and control groups (8.9% and 7.9%, respectively), and the association between PsA and a higher risk for all-cause mortality was not significant (hazard ratio, 1.02; 95% confidence interval, 0.90-1.15). In the general population, malignancy (26.0%) and ischemic heart disease (15.8%) were the leading causes of death in patients with PsA.

Study details: Findings are from an analysis of a cohort of 5,275 adults newly diagnosed with PsA between 2003 and 2018, matched with 21,011 control participants and followed for 7.2±4.4 years.

Disclosures: The study did not report any source of funding. No conflict of interests was reported.

Source: Haddad A et al. J Rheumatol. 2021 Jul 15. doi: 10.3899/jrheum.210159. 

Key clinical point: Oligoarticular psoriatic arthritis (PsA) is similar to polyarticular disease. However, involvement of lower extremity small joint had the highest chances of polyarticular presentation, whereas low Short Form-36 (SF-36) Mental Component Summary (MCS) score was significantly associated with progression from oligoarthritis to polyarthritis.

Major finding: Demographics and clinical characteristics were similar between the oligoarticular and polyarticular PsA groups. However, polyarticular PsA was associated with higher odds of lower extremity small joints (odds ratio, 17.15; P < .001). Among patients with oligoarticular PsA, 39% developed polyarticular PsA with lower SF-36 MCS being the only predictor for progression (hazard ratio, 0.97; P = .01).

Study details: Findings are from a longitudinal study including 407 patients with PsA who entered the University of Toronto PsA clinic within 12 months of diagnosis between 1978 and 2018, of which 47% presented with oligoarthritis and 53% with polyarthritis.

Disclosures: The University of Toronto PsA program was funded by the Krembil Foundation. The authors declared no conflict of interests.

Source: Gladman DD et al. J Rheumatol. 2021 Aug 1. doi: 10.3899/jrheum.210434.

Key clinical point: Oligoarticular psoriatic arthritis (PsA) is similar to polyarticular disease. However, involvement of lower extremity small joint had the highest chances of polyarticular presentation, whereas low Short Form-36 (SF-36) Mental Component Summary (MCS) score was significantly associated with progression from oligoarthritis to polyarthritis.

Major finding: Demographics and clinical characteristics were similar between the oligoarticular and polyarticular PsA groups. However, polyarticular PsA was associated with higher odds of lower extremity small joints (odds ratio, 17.15; P < .001). Among patients with oligoarticular PsA, 39% developed polyarticular PsA with lower SF-36 MCS being the only predictor for progression (hazard ratio, 0.97; P = .01).

Study details: Findings are from a longitudinal study including 407 patients with PsA who entered the University of Toronto PsA clinic within 12 months of diagnosis between 1978 and 2018, of which 47% presented with oligoarthritis and 53% with polyarthritis.

Disclosures: The University of Toronto PsA program was funded by the Krembil Foundation. The authors declared no conflict of interests.

Source: Gladman DD et al. J Rheumatol. 2021 Aug 1. doi: 10.3899/jrheum.210434.

Key clinical point: Oligoarticular psoriatic arthritis (PsA) is similar to polyarticular disease. However, involvement of lower extremity small joint had the highest chances of polyarticular presentation, whereas low Short Form-36 (SF-36) Mental Component Summary (MCS) score was significantly associated with progression from oligoarthritis to polyarthritis.

Major finding: Demographics and clinical characteristics were similar between the oligoarticular and polyarticular PsA groups. However, polyarticular PsA was associated with higher odds of lower extremity small joints (odds ratio, 17.15; P < .001). Among patients with oligoarticular PsA, 39% developed polyarticular PsA with lower SF-36 MCS being the only predictor for progression (hazard ratio, 0.97; P = .01).

Study details: Findings are from a longitudinal study including 407 patients with PsA who entered the University of Toronto PsA clinic within 12 months of diagnosis between 1978 and 2018, of which 47% presented with oligoarthritis and 53% with polyarthritis.

Disclosures: The University of Toronto PsA program was funded by the Krembil Foundation. The authors declared no conflict of interests.

Source: Gladman DD et al. J Rheumatol. 2021 Aug 1. doi: 10.3899/jrheum.210434.

Key clinical point: Secukinumab was effective in treating patients with psoriatic arthritis (PsA) in real-world clinical settings and generated high levels of satisfaction among physicians.

Major finding: At treatment initiation, 5.6%, 16.3%, and 8.7% of patients were categorized with mild disease, skin, and joint severity, which increased to 75.5%, 83.6%, and 77.6%, respectively, at the current consultation. Patients with Psoriasis Area Severity Index scores of less than 3 increased from 7.1% at treatment initiation to 64.3% at the current consultation. Physician satisfaction with secukinumab treatment was greater than 90% irrespective of disease severity at initiation and several other clinical parameters.

Study details: Findings are from a retrospective analysis of data collected for 572 patients with mild-to-severe PsA from 294 rheumatologists and 144 dermatologists. Included patients received either secukinumab 300 mg or 150 mg for at least 4 months.

Disclosures: This study was funded by Novartis. Dr. Conaghan and Dr. Kiltz declared receiving consultancy or speaker fees and/or research support from several sources including Novartis.

Source: Conaghan PG et al. Curr Med Res Opin. 2021 Jul 23. doi: 10.1080/03007995.2021.1954500.

Key clinical point: Secukinumab was effective in treating patients with psoriatic arthritis (PsA) in real-world clinical settings and generated high levels of satisfaction among physicians.

Major finding: At treatment initiation, 5.6%, 16.3%, and 8.7% of patients were categorized with mild disease, skin, and joint severity, which increased to 75.5%, 83.6%, and 77.6%, respectively, at the current consultation. Patients with Psoriasis Area Severity Index scores of less than 3 increased from 7.1% at treatment initiation to 64.3% at the current consultation. Physician satisfaction with secukinumab treatment was greater than 90% irrespective of disease severity at initiation and several other clinical parameters.

Study details: Findings are from a retrospective analysis of data collected for 572 patients with mild-to-severe PsA from 294 rheumatologists and 144 dermatologists. Included patients received either secukinumab 300 mg or 150 mg for at least 4 months.

Disclosures: This study was funded by Novartis. Dr. Conaghan and Dr. Kiltz declared receiving consultancy or speaker fees and/or research support from several sources including Novartis.

Source: Conaghan PG et al. Curr Med Res Opin. 2021 Jul 23. doi: 10.1080/03007995.2021.1954500.

Key clinical point: Secukinumab was effective in treating patients with psoriatic arthritis (PsA) in real-world clinical settings and generated high levels of satisfaction among physicians.

Major finding: At treatment initiation, 5.6%, 16.3%, and 8.7% of patients were categorized with mild disease, skin, and joint severity, which increased to 75.5%, 83.6%, and 77.6%, respectively, at the current consultation. Patients with Psoriasis Area Severity Index scores of less than 3 increased from 7.1% at treatment initiation to 64.3% at the current consultation. Physician satisfaction with secukinumab treatment was greater than 90% irrespective of disease severity at initiation and several other clinical parameters.

Study details: Findings are from a retrospective analysis of data collected for 572 patients with mild-to-severe PsA from 294 rheumatologists and 144 dermatologists. Included patients received either secukinumab 300 mg or 150 mg for at least 4 months.

Disclosures: This study was funded by Novartis. Dr. Conaghan and Dr. Kiltz declared receiving consultancy or speaker fees and/or research support from several sources including Novartis.

Source: Conaghan PG et al. Curr Med Res Opin. 2021 Jul 23. doi: 10.1080/03007995.2021.1954500.

Key clinical point: Independent of loading dose, secukinumab provided low rates of radiographic progression over 2 years in patients with active psoriatic arthritis (PsA).

Major finding: At 2 years, proportions of patients with no radiographic progression with secukinumab 300 mg, 150 mg, and 150 mg no load were 89.5%, 82.3%, and 81.1%, respectively. Radiographic damage assessed by the mean change from baseline in van der Heijde-modified total Sharp score was 0.10±1.74, 0.52±2.66, and 0.41±2.20 in the secukinumab 300 mg, 150 mg, and 150 mg no-load groups, respectively.

Study details: Findings are end-of-study results from the phase 3 FUTURE 5 trial including 783 patients with active PsA who were randomly assigned to receive secukinumab 300 mg, secukinumab 150 mg with/without loading dose, or placebo for 4 consecutive weeks and every 4 weeks subsequently.

Disclosures: This study was funded by Novartis Pharma. Some of the authors declared receiving research grants and consulting and speaker fees from various sources including Novartis. Four authors declared being past or current employees and/or shareholders of Novartis.

Source: Mease PJ et al. RMD Open. 2021 Jul 30. doi: 10.1136/rmdopen-2021-001600.

Key clinical point: Independent of loading dose, secukinumab provided low rates of radiographic progression over 2 years in patients with active psoriatic arthritis (PsA).

Major finding: At 2 years, proportions of patients with no radiographic progression with secukinumab 300 mg, 150 mg, and 150 mg no load were 89.5%, 82.3%, and 81.1%, respectively. Radiographic damage assessed by the mean change from baseline in van der Heijde-modified total Sharp score was 0.10±1.74, 0.52±2.66, and 0.41±2.20 in the secukinumab 300 mg, 150 mg, and 150 mg no-load groups, respectively.

Study details: Findings are end-of-study results from the phase 3 FUTURE 5 trial including 783 patients with active PsA who were randomly assigned to receive secukinumab 300 mg, secukinumab 150 mg with/without loading dose, or placebo for 4 consecutive weeks and every 4 weeks subsequently.

Disclosures: This study was funded by Novartis Pharma. Some of the authors declared receiving research grants and consulting and speaker fees from various sources including Novartis. Four authors declared being past or current employees and/or shareholders of Novartis.

Source: Mease PJ et al. RMD Open. 2021 Jul 30. doi: 10.1136/rmdopen-2021-001600.

Key clinical point: Independent of loading dose, secukinumab provided low rates of radiographic progression over 2 years in patients with active psoriatic arthritis (PsA).

Major finding: At 2 years, proportions of patients with no radiographic progression with secukinumab 300 mg, 150 mg, and 150 mg no load were 89.5%, 82.3%, and 81.1%, respectively. Radiographic damage assessed by the mean change from baseline in van der Heijde-modified total Sharp score was 0.10±1.74, 0.52±2.66, and 0.41±2.20 in the secukinumab 300 mg, 150 mg, and 150 mg no-load groups, respectively.

Study details: Findings are end-of-study results from the phase 3 FUTURE 5 trial including 783 patients with active PsA who were randomly assigned to receive secukinumab 300 mg, secukinumab 150 mg with/without loading dose, or placebo for 4 consecutive weeks and every 4 weeks subsequently.

Disclosures: This study was funded by Novartis Pharma. Some of the authors declared receiving research grants and consulting and speaker fees from various sources including Novartis. Four authors declared being past or current employees and/or shareholders of Novartis.

Source: Mease PJ et al. RMD Open. 2021 Jul 30. doi: 10.1136/rmdopen-2021-001600.

Key clinical point: Janus kinase (JAK) inhibitors are an effective and safe treatment option for psoriatic arthritis (PsA).

Major finding: The American College of Rheumatology 20 response was significantly higher with JAK inhibitors vs placebo (odds ratio [OR], 3.78; 95% confidence interval [CI], 2.72-5.24). The risk for serious adverse events was not significantly higher with JAK inhibitors vs placebo (OR, 1.12; 95% CI, 0.14-2.82).

Study details: Findings are from a meta-analysis of 5 randomized controlled trials including 3,293 adult patients with PsA who were treated with JAK inhibitors or placebo.

Disclosures: The study did not report any source of funding. No conflict of interests was reported.

Source: Campanero F et al. Autoimmun Rev. 2021 Jul 15. doi: 10.1016/j.autrev.2021.102902.

Key clinical point: Janus kinase (JAK) inhibitors are an effective and safe treatment option for psoriatic arthritis (PsA).

Major finding: The American College of Rheumatology 20 response was significantly higher with JAK inhibitors vs placebo (odds ratio [OR], 3.78; 95% confidence interval [CI], 2.72-5.24). The risk for serious adverse events was not significantly higher with JAK inhibitors vs placebo (OR, 1.12; 95% CI, 0.14-2.82).

Study details: Findings are from a meta-analysis of 5 randomized controlled trials including 3,293 adult patients with PsA who were treated with JAK inhibitors or placebo.

Disclosures: The study did not report any source of funding. No conflict of interests was reported.

Source: Campanero F et al. Autoimmun Rev. 2021 Jul 15. doi: 10.1016/j.autrev.2021.102902.

Key clinical point: Janus kinase (JAK) inhibitors are an effective and safe treatment option for psoriatic arthritis (PsA).

Major finding: The American College of Rheumatology 20 response was significantly higher with JAK inhibitors vs placebo (odds ratio [OR], 3.78; 95% confidence interval [CI], 2.72-5.24). The risk for serious adverse events was not significantly higher with JAK inhibitors vs placebo (OR, 1.12; 95% CI, 0.14-2.82).

Study details: Findings are from a meta-analysis of 5 randomized controlled trials including 3,293 adult patients with PsA who were treated with JAK inhibitors or placebo.

Disclosures: The study did not report any source of funding. No conflict of interests was reported.

Source: Campanero F et al. Autoimmun Rev. 2021 Jul 15. doi: 10.1016/j.autrev.2021.102902.

Key clinical point: Treating skin with biological disease-modifying antirheumatic drugs (bDMARDs) may reduce the risk of developing psoriatic arthritis (PsA) in patients with psoriasis.

Major finding: Patients with psoriasis had a significantly lower risk of developing PsA when treated with bDMARDs vs topics (incidence rate ratio, 0.26; P = .0111). The use of bDMARDs was also protective against PsA development compared with topical/no treatment (hazard ratio, 0.19; P = .025).

Study details: Findings are from a retrospective cohort study including 1,719 patients with psoriasis, of which 1,387, 229, and 103 patients were treated with topics, conventional DMARDs, and bDMARDs, respectively.

Disclosures: This study was supported by a grant from the Pan-American League of Associations for Rheumatology. Few of the authors declared receiving grants, speaker fees, and/or consulting fees outside the submitted work from various sources.

Source: Acosta Felquer ML et al. Ann Rheum Dis. 2021 Jul 19. doi: 10.1136/annrheumdis-2021-220865.

Key clinical point: Treating skin with biological disease-modifying antirheumatic drugs (bDMARDs) may reduce the risk of developing psoriatic arthritis (PsA) in patients with psoriasis.

Major finding: Patients with psoriasis had a significantly lower risk of developing PsA when treated with bDMARDs vs topics (incidence rate ratio, 0.26; P = .0111). The use of bDMARDs was also protective against PsA development compared with topical/no treatment (hazard ratio, 0.19; P = .025).

Study details: Findings are from a retrospective cohort study including 1,719 patients with psoriasis, of which 1,387, 229, and 103 patients were treated with topics, conventional DMARDs, and bDMARDs, respectively.

Disclosures: This study was supported by a grant from the Pan-American League of Associations for Rheumatology. Few of the authors declared receiving grants, speaker fees, and/or consulting fees outside the submitted work from various sources.

Source: Acosta Felquer ML et al. Ann Rheum Dis. 2021 Jul 19. doi: 10.1136/annrheumdis-2021-220865.

Key clinical point: Treating skin with biological disease-modifying antirheumatic drugs (bDMARDs) may reduce the risk of developing psoriatic arthritis (PsA) in patients with psoriasis.

Major finding: Patients with psoriasis had a significantly lower risk of developing PsA when treated with bDMARDs vs topics (incidence rate ratio, 0.26; P = .0111). The use of bDMARDs was also protective against PsA development compared with topical/no treatment (hazard ratio, 0.19; P = .025).

Study details: Findings are from a retrospective cohort study including 1,719 patients with psoriasis, of which 1,387, 229, and 103 patients were treated with topics, conventional DMARDs, and bDMARDs, respectively.

Disclosures: This study was supported by a grant from the Pan-American League of Associations for Rheumatology. Few of the authors declared receiving grants, speaker fees, and/or consulting fees outside the submitted work from various sources.

Source: Acosta Felquer ML et al. Ann Rheum Dis. 2021 Jul 19. doi: 10.1136/annrheumdis-2021-220865.

Key clinical point: Most patients with psoriatic arthritis (PsA) experienced mildly severe psoriasis, but it had an impact on their health-related quality of life (HRQoL) when assessed using a dermatology-specific HRQoL questionnaire (Skindex-17).

Major finding: The majority of patients (71%) had mild psoriasis and remained in this category at 12 months of follow-up. Psoriasis severity did not fluctuate much during the first year with the proportion of patients without psoriasis increasing from 17% at baseline to 34% and those with severe psoriasis remaining stable with 3% at baseline and 2% at 12 months. Psoriasis Area Severity Index score was significantly associated with a psychosocial subscale of Skindex-17 at baseline (incidence rate ratio [IRR], 1.05; 95% confidence interval [CI], 1.02-1.08) and 12 months (IRR, 1.10; 95% CI, 1.05-1.15).

Study details: Findings are from a Dutch cohort including 644 patients with newly diagnosed PsA who were followed up for 1 year.

Disclosures: The study received no specific funding. The authors declared no conflict of interests.

Source: Kasiem FR et al. Rheumatology. 2021 Jul 24. doi: 10.1093/rheumatology/keab606.

Key clinical point: Most patients with psoriatic arthritis (PsA) experienced mildly severe psoriasis, but it had an impact on their health-related quality of life (HRQoL) when assessed using a dermatology-specific HRQoL questionnaire (Skindex-17).

Major finding: The majority of patients (71%) had mild psoriasis and remained in this category at 12 months of follow-up. Psoriasis severity did not fluctuate much during the first year with the proportion of patients without psoriasis increasing from 17% at baseline to 34% and those with severe psoriasis remaining stable with 3% at baseline and 2% at 12 months. Psoriasis Area Severity Index score was significantly associated with a psychosocial subscale of Skindex-17 at baseline (incidence rate ratio [IRR], 1.05; 95% confidence interval [CI], 1.02-1.08) and 12 months (IRR, 1.10; 95% CI, 1.05-1.15).

Study details: Findings are from a Dutch cohort including 644 patients with newly diagnosed PsA who were followed up for 1 year.

Disclosures: The study received no specific funding. The authors declared no conflict of interests.

Source: Kasiem FR et al. Rheumatology. 2021 Jul 24. doi: 10.1093/rheumatology/keab606.

Key clinical point: Most patients with psoriatic arthritis (PsA) experienced mildly severe psoriasis, but it had an impact on their health-related quality of life (HRQoL) when assessed using a dermatology-specific HRQoL questionnaire (Skindex-17).

Major finding: The majority of patients (71%) had mild psoriasis and remained in this category at 12 months of follow-up. Psoriasis severity did not fluctuate much during the first year with the proportion of patients without psoriasis increasing from 17% at baseline to 34% and those with severe psoriasis remaining stable with 3% at baseline and 2% at 12 months. Psoriasis Area Severity Index score was significantly associated with a psychosocial subscale of Skindex-17 at baseline (incidence rate ratio [IRR], 1.05; 95% confidence interval [CI], 1.02-1.08) and 12 months (IRR, 1.10; 95% CI, 1.05-1.15).

Study details: Findings are from a Dutch cohort including 644 patients with newly diagnosed PsA who were followed up for 1 year.

Disclosures: The study received no specific funding. The authors declared no conflict of interests.

Source: Kasiem FR et al. Rheumatology. 2021 Jul 24. doi: 10.1093/rheumatology/keab606.

Key clinical point: Guselkumab 100 mg every 4 weeks (Q4W) or 8 weeks (Q8W) provided a clinically meaningful reduction in fatigue in patients with active psoriatic arthritis (PsA).

Major finding: At week 24, a higher proportion of patients receiving guselkumab Q4W (63%; P less than .001) and Q8W (54%; P less than .01) vs placebo (35%) achieved 4-point or higher improvement in Functional Assessment of Chronic Illness Therapy-Fatigue scores in DISCOVER-1. Findings were similar with guselkumab Q4W (60%; P less than .01) and Q8W (61%; P less than .001) vs placebo (46%) in DISCOVER-2. Improvements were maintained until week 52.

Study details: Findings are from the analysis of 2 phase 3 trials (DISCOVER 1 and DISCOVER 2) including 1,120 patients with active PsA who were randomly assigned to guselkumab 100 mg at week 0 and then Q4W, guselkumab 100 mg at weeks 0 and 4 and then Q8W, or placebo Q4W.

Disclosures: This study was funded by Janssen Research & Development, LLC. Some of the authors declared receiving grants, consulting fees, and speaker’s bureau support from various sources including Janssen. Seven of the authors declared being employees and stockholders of Johnson & Johnson.

Source: Rahman P et al. Arthritis Res Ther. 2021 Jul 14. doi: 10.1186/s13075-021-02554-3.

Key clinical point: Guselkumab 100 mg every 4 weeks (Q4W) or 8 weeks (Q8W) provided a clinically meaningful reduction in fatigue in patients with active psoriatic arthritis (PsA).

Major finding: At week 24, a higher proportion of patients receiving guselkumab Q4W (63%; P less than .001) and Q8W (54%; P less than .01) vs placebo (35%) achieved 4-point or higher improvement in Functional Assessment of Chronic Illness Therapy-Fatigue scores in DISCOVER-1. Findings were similar with guselkumab Q4W (60%; P less than .01) and Q8W (61%; P less than .001) vs placebo (46%) in DISCOVER-2. Improvements were maintained until week 52.

Study details: Findings are from the analysis of 2 phase 3 trials (DISCOVER 1 and DISCOVER 2) including 1,120 patients with active PsA who were randomly assigned to guselkumab 100 mg at week 0 and then Q4W, guselkumab 100 mg at weeks 0 and 4 and then Q8W, or placebo Q4W.

Disclosures: This study was funded by Janssen Research & Development, LLC. Some of the authors declared receiving grants, consulting fees, and speaker’s bureau support from various sources including Janssen. Seven of the authors declared being employees and stockholders of Johnson & Johnson.

Source: Rahman P et al. Arthritis Res Ther. 2021 Jul 14. doi: 10.1186/s13075-021-02554-3.

Key clinical point: Guselkumab 100 mg every 4 weeks (Q4W) or 8 weeks (Q8W) provided a clinically meaningful reduction in fatigue in patients with active psoriatic arthritis (PsA).

Major finding: At week 24, a higher proportion of patients receiving guselkumab Q4W (63%; P less than .001) and Q8W (54%; P less than .01) vs placebo (35%) achieved 4-point or higher improvement in Functional Assessment of Chronic Illness Therapy-Fatigue scores in DISCOVER-1. Findings were similar with guselkumab Q4W (60%; P less than .01) and Q8W (61%; P less than .001) vs placebo (46%) in DISCOVER-2. Improvements were maintained until week 52.

Study details: Findings are from the analysis of 2 phase 3 trials (DISCOVER 1 and DISCOVER 2) including 1,120 patients with active PsA who were randomly assigned to guselkumab 100 mg at week 0 and then Q4W, guselkumab 100 mg at weeks 0 and 4 and then Q8W, or placebo Q4W.

Disclosures: This study was funded by Janssen Research & Development, LLC. Some of the authors declared receiving grants, consulting fees, and speaker’s bureau support from various sources including Janssen. Seven of the authors declared being employees and stockholders of Johnson & Johnson.

Source: Rahman P et al. Arthritis Res Ther. 2021 Jul 14. doi: 10.1186/s13075-021-02554-3.

Key clinical point: Radiofrequency ablation was associated with improved survival in HCC patients with early and intermediate stage HCC.

Major finding: The survival in patients with liver cancer due to HCC was 82.3% at 12 months and 57.8% at 36 months for patients who received radiofrequency ablation.

Study details: The data come from a retrospective cohort study of 62 adults with HCC; of these, 32.3% were early stage, based on Barcelona-Clinic Liver Cancer staging system (BCLC) A, and 67.7% were intermediate, based on BCLC B. A total of 46 patients underwent radiofrequency ablation as their first-line treatment.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Sulaiman AS et al. J Gastrointest Cancer. 2021 Aug 11. doi: 10.1007/s12029-021-00676-0.

Key clinical point: Radiofrequency ablation was associated with improved survival in HCC patients with early and intermediate stage HCC.

Major finding: The survival in patients with liver cancer due to HCC was 82.3% at 12 months and 57.8% at 36 months for patients who received radiofrequency ablation.

Study details: The data come from a retrospective cohort study of 62 adults with HCC; of these, 32.3% were early stage, based on Barcelona-Clinic Liver Cancer staging system (BCLC) A, and 67.7% were intermediate, based on BCLC B. A total of 46 patients underwent radiofrequency ablation as their first-line treatment.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Sulaiman AS et al. J Gastrointest Cancer. 2021 Aug 11. doi: 10.1007/s12029-021-00676-0.

Key clinical point: Radiofrequency ablation was associated with improved survival in HCC patients with early and intermediate stage HCC.

Major finding: The survival in patients with liver cancer due to HCC was 82.3% at 12 months and 57.8% at 36 months for patients who received radiofrequency ablation.

Study details: The data come from a retrospective cohort study of 62 adults with HCC; of these, 32.3% were early stage, based on Barcelona-Clinic Liver Cancer staging system (BCLC) A, and 67.7% were intermediate, based on BCLC B. A total of 46 patients underwent radiofrequency ablation as their first-line treatment.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Sulaiman AS et al. J Gastrointest Cancer. 2021 Aug 11. doi: 10.1007/s12029-021-00676-0.

Key clinical point: A treatment strategy of drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) showed similar rates of survival and adverse events in patients with HCC adjacent to the gallbladder

Major finding: At one month after treatment, complete response rate, objective response rate and disease control rate were 79.2%, 95.8% and 100.0% in the DEB-TACE plus MWA group. Rates of recurrence-free survival, progression-free survival, and overall survival were similar between the DEB-TACE plus MWA group and the standard surgery group.

Study details: The data come from 54 adults with HCC adjacent to the gallbladder. Of these, 24 patients underwent either drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) and 30 underwent standard surgery.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Cai L et al. Am J Transl Res. 2021 Jul 15. PMCID:  PMC8340149

Key clinical point: A treatment strategy of drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) showed similar rates of survival and adverse events in patients with HCC adjacent to the gallbladder

Major finding: At one month after treatment, complete response rate, objective response rate and disease control rate were 79.2%, 95.8% and 100.0% in the DEB-TACE plus MWA group. Rates of recurrence-free survival, progression-free survival, and overall survival were similar between the DEB-TACE plus MWA group and the standard surgery group.

Study details: The data come from 54 adults with HCC adjacent to the gallbladder. Of these, 24 patients underwent either drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) and 30 underwent standard surgery.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Cai L et al. Am J Transl Res. 2021 Jul 15. PMCID:  PMC8340149

Key clinical point: A treatment strategy of drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) showed similar rates of survival and adverse events in patients with HCC adjacent to the gallbladder

Major finding: At one month after treatment, complete response rate, objective response rate and disease control rate were 79.2%, 95.8% and 100.0% in the DEB-TACE plus MWA group. Rates of recurrence-free survival, progression-free survival, and overall survival were similar between the DEB-TACE plus MWA group and the standard surgery group.

Study details: The data come from 54 adults with HCC adjacent to the gallbladder. Of these, 24 patients underwent either drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) and 30 underwent standard surgery.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Cai L et al. Am J Transl Res. 2021 Jul 15. PMCID:  PMC8340149